Participants were HIV-1-infected partners randomized to early ART ( CD4 350-550 ) in HPTN052 ( n = 886 , median follow-up = 2.1 years ) , a clinical trial of early ART to prevent sexual transmission of HIV-1 in serodiscordant couples at 13 sites in 9 countries .